source
- Incyte claims double Phase 3 win in vitiligo, will file for approvalIncyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...Endpoints · 3mo ago↗ source
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsTavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.BioPharma Dive · 3mo ago↗ source
- Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire KestrelThe pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma gia…